The first targeted drug accredited to the strong skin condition

(MedPage Today) – DUPILUMAB (DUPIXent) adopted from the DUPIXENT Department as the first targeted drug for the bubble pimpix, which is a rare skin disease that greatly affects elderly patients, and the treatment of Sanofi and Regeneron. Approval of the injection …